ASX / Media Release 30 October 2026 September Quarterly Activities Report & Appendix 4C Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) a biopharmaceutical company focused on the development and commercialisation of Exenatide for neurological conditions relating to raised intracranial...